Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
VIVincerx Pharma, Inc. logo

Vincerx Pharma, Inc. (VINC)

Other OTC · Currency in USD
$0.02 ▲ +0.00 (+0.00%)
At close: Oct 23, 11:39 AM ET. Market closed.

Summary

Previous Close
$0.02
Open
$0.02
Day's Range
$0.02 – $0.02
52 Week Range
$0.00 – $1.43
Volume
251
Avg. Volume
2,589
Market Cap
$78.51K
Beta (5Y Monthly)
1.46
PE Ratio (TTM)
--
EPS (TTM)
-$5.75
Earnings Date
Nov 10, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$3.00

Profile: Vincerx Pharma, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
13
CEO
Raquel E. Izumi

Vincerx Pharma, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering and advancing innovative treatments for cancer, specifically addressing areas of high medical need within the U.S. Its primary therapeutic asset is VIP152, an inhibitor targeting cyclin-dependent kinase-9 (CDK9), designed for individuals battling advanced forms of cancer. Beyond this lead candidate, the company's pipeline features several preclinical-stage projects: VIP217, an orally administered PTEFb/CDK9 inhibitor; VIP236, a small molecule drug conjugate aimed at solid tumor treatment; and VIP943 and VIP924, both geared towards treating blood cancers.

Earnings

Next report: Tue, Nov 10, 2026
EPS estimate -$8.00
DateEst.Actual
May 15, 2025–-$0.91
Mar 27, 2025-$3.40-$4.20Miss
Nov 12, 2024-$3.40-$3.40Beat
Aug 8, 2024-$3.40-$1.00Beat
May 14, 2024-$0.26-$6.80Miss
Mar 29, 2024-$8.40-$4.60Beat

Analyst view

Consensus price target
$3.00 ▲ +19,900.0%
Range $2.00 – $4.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on VINC and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.